CTLA4 and psoriasis: A grade 2 rash was observed in a patient with psoriasis (28 days after the combination of PD-L1 inhibitor + CTLA-4 inhibitor), a grade 2 immune-related pneumonitis was observed in one patient with rheumatoid arthritis (68 days after starting the combination of chemotherapy and PD-L1 inhibitor), and one patient presented with a tuberculosis relapse (178 days after chemotherapy combined with PD-L1 inhibitor).